Testosterone for women: what the evidence actually supports

What testosterone does in women

Testosterone is not just a male hormone. Women make it in the ovaries and adrenal glands, and it circulates at far lower levels than in men. It contributes to sexual desire and arousal and plays a supporting role alongside estrogen in tissue and bone metabolism. Levels drift down gradually with age rather than dropping sharply at menopause, and there is no single testosterone number that reliably defines a deficiency in women.

Because normal female concentrations are so low and overlap widely between women with and without symptoms, a blood test alone cannot diagnose "low testosterone." For the reference ranges by age and how testosterone tracks across the lifespan, see our dedicated chart rather than a restatement here.

See the reference ranges and lifespan trend on our testosterone levels in women by age chart, or the symptom overview for low testosterone in women.

The one evidence-supported use: HSDD after menopause

The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women — endorsed by a coalition of menopause and endocrine societies — reached a single clear conclusion: the only evidence-based indication for testosterone in women is hypoactive sexual desire disorder (HSDD) in postmenopausal women. HSDD means a persistent, distressing absence of sexual thoughts or desire that is not explained by another cause such as relationship issues, depression, medication side effects, or untreated genitourinary symptoms.

A 2019 systematic review and meta-analysis in The Lancet Diabetes & Endocrinology pooled randomized trial data and found that testosterone produced a modest but statistically meaningful improvement in sexual desire, arousal, orgasm, and sexual satisfaction in postmenopausal women, compared with placebo or estrogen alone. The effect is real but moderate — testosterone is not a guaranteed or dramatic fix, and it is considered only after other contributors to low desire have been addressed.

What the evidence does NOT support

This is where the marketing and the science part ways. The same 2019 meta-analysis and the global consensus statement found insufficient evidence to recommend testosterone for any non-sexual symptom in women. That includes low energy and fatigue, mood or depressive symptoms, cognitive complaints or "brain fog," bone density, muscle mass, and general wellbeing or anti-aging benefits.

In short, if testosterone is being sold to you for energy, motivation, weight, or mental clarity, the current evidence does not back that claim. Prescribing testosterone for those reasons is not supported by the consensus statement, and the long-term safety of testosterone in women — particularly effects on the heart and breast — has not been established, which is another reason experts advise against broad, indefinite use.

No FDA-approved female product: what actually gets prescribed

There is no testosterone product approved by the FDA specifically for women in the United States. In practice, clinicians who prescribe it use a male-approved transdermal testosterone gel at approximately one-tenth of the standard male dose, aiming to keep blood levels within the normal premenopausal female range. Because these products are designed and metered for men, precise low-dose measuring can be difficult, and accidental transfer to a partner or child is a real caution.

The other route is a compounded testosterone cream or troche made by a compounding pharmacy. Compounded products are not FDA-reviewed for potency or consistency, so the actual dose delivered can vary. The 2019 consensus statement specifically cautions against compounded testosterone and against pellet implants and injections, which can push levels well above the female range. Whichever form is used, the goal is female-range dosing, not male-range replacement.

Monitoring, side effects, and virilization

When testosterone is used appropriately, a clinician typically checks a baseline total testosterone level, re-checks after starting to confirm the level stays within the normal female range, and reassesses whether sexual symptoms have actually improved after a trial of a few months. If there is no meaningful benefit within about six months, guidelines suggest stopping.

The most common side effects are dose-related: acne and increased body or facial hair (hirsutism). At excessive doses, women can develop signs of virilization — deepening of the voice, male-pattern hair loss, or clitoral enlargement — and some of these changes may not fully reverse even after stopping. This is precisely why female-range dosing and monitoring matter, and why pellets, injections, and unmonitored compounded regimens raise concern.

How it is prescribed via telehealth

Several menopause and women's sexual-health telehealth services evaluate low desire and, when appropriate, prescribe off-label testosterone alongside standard menopause care. A responsible evaluation should first rule out other causes of low desire — genitourinary symptoms, mood, medications, thyroid, and relationship factors — before considering testosterone, and should include lab monitoring rather than prescribing blind.

Testosterone for women is a prescription decision that rests with a licensed clinician who knows your history; this page is educational and does not recommend a dose or product. If you want to compare menopause providers, some of which offer off-label testosterone for libido as an add-on, the options below are a starting point.

A note on prescribing

Testosterone for women is used off-label, has no FDA-approved female product, and is a decision for a licensed clinician who can rule out other causes of low desire and monitor your blood levels. This page is informational and does not recommend a dose. To see how testosterone fits alongside estrogen and progesterone options, read our hormone therapy options visual guide.

Related reading

• Testosterone levels in women by age
• Menopause and low libido
• Hormone therapy options: a visual guide
• Best menopause telehealth providers

Frequently asked questions

Is there an FDA-approved testosterone for women?

No. There is no testosterone product approved by the FDA for use in women in the United States. When testosterone is prescribed to women it is off-label — typically a male-approved transdermal gel used at about one-tenth of the male dose, or a compounded formulation. Any use should be supervised and monitored by a clinician.

What is the only evidence-based use of testosterone in women?

According to the 2019 Global Consensus Position Statement, the only evidence-supported indication is hypoactive sexual desire disorder (HSDD) in postmenopausal women — a persistent, distressing lack of sexual desire not explained by another cause. The evidence does not support testosterone for energy, mood, cognition, or bone health.

Does testosterone help with energy, mood, or brain fog?

The current evidence does not support using testosterone for energy, fatigue, mood, or cognitive symptoms in women. A 2019 meta-analysis of randomized trials found benefit only for sexual function in postmenopausal women and found insufficient evidence for non-sexual outcomes. Claims that testosterone boosts energy or mental clarity are not backed by the trial data.

What are the side effects of testosterone in women?

The most common side effects are acne and unwanted hair growth, both dose-related. At excessive doses women can develop virilization — a deeper voice, scalp hair loss, or clitoral enlargement — and some of these changes may not fully reverse. Long-term effects on the heart and breast are not established, so female-range dosing and monitoring are important.

How is testosterone for women prescribed and monitored?

A clinician usually checks a baseline testosterone level, uses a male-approved gel at roughly one-tenth the male dose to keep levels within the normal female range, rechecks the level, and reassesses sexual symptoms after a few months. If there is no meaningful benefit within about six months, guidelines suggest stopping. Pellets and injections are generally discouraged.

Primary medical sources

1. guidelineDavis SR, et al. "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." J Clin Endocrinol Metab 2019;104(10):4660-4666.
2. PubMedIslam RM, et al. "Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data." Lancet Diabetes Endocrinol 2019;7(10):754-766.
3. guidelineParish SJ, et al. "International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women." J Sex Med 2021;18(5):849-867.
4. NAMSThe North American Menopause Society. "The 2022 hormone therapy position statement of The North American Menopause Society." Menopause 2022;29(7):767-794.